Automated 22-kD growth hormone-specific assay without interference from pegvisomant

Clinical Chemistry

Volumn 58, Issue 10, 2012, Pages 1446-1456

  Manolopoulou, Jenny ^a   Alami, Younes ^b   Petersenn, Stephan ^c,d   Schopohl, Jochen ^a   Wu, Zida ^e   Strasburger, Christian J ^e   Bidlingmaier, Martin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b IDS Ltd   (Belgium)

^c ENDOC Center for Endocrine Tumors   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; MONOCLONAL ANTIBODY; PEGVISOMANT;

ACROMEGALY; ANTIBODY AFFINITY; ARTICLE; AUTOANALYZER; CALIBRATION; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; STANDARDIZATION; VALIDATION PROCESS;

ACROMEGALY; ANTIBODIES, MONOCLONAL; AUTOANALYSIS; CROSS REACTIONS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; IMMUNOASSAY; MALE; PROTEIN ISOFORMS; SENSITIVITY AND SPECIFICITY;

EID: 84866988839     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.188128     Document Type: Article

References (42)

1. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 2011;57:555-9.
2. Bidlingmaier M, Freda PU. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm IGF Res 2010;20:19-25.
3. Baumann GP. Growth hormone isoforms. Growth Horm IGF Res 2009;19:333-40.
4. Seth J, Ellis A, Al-Sadie R. Serum growth hormone measurements in clinical practice: an audit of performance from the UK National External Quality Assessment scheme. Horm Res 1999;51:13-9. (Pubitemid 29301278)
5. Popii V, Baumann G. Laboratory measurement of growth hormone. Clin Chim Acta 2004;350:1-16. (Pubitemid 39458242)
6. Wieringa GE, Trainer PJ. Commentary: Harmonizing harmonizing growth hormone measurements: learning lessons for the future. J Clin Endocrinol Metab 2007;92:2874-5. (Pubitemid 47236342)
7. Trainer PJ, Barth J, Sturgeon C, Wieringaon G. Consensus statement on the standardisation of GH assays. Eur J Endocrinol 2006;155:1-2. (Pubitemid 44103367)
8. Bristow AF, Jespersen AM. The second international standard for somatropin (recombinant DNA-derived human growth hormone): preparation and calibration in an international collaborative study. Biologicals 2001;29:97-106. (Pubitemid 32977038)
9. Tanaka T, Tachibana K, Shimatsu A, Katsumata N, Tsushima T, Hizuka N, et al. A nationwide attempt to standardize growth hormone assays. Horm Res 64 2005;(Suppl 2):6-11.
10. Ranke MB, Orskov H, Bristow AF, Seth J, Baumann G. Consensus on how to measure growth hormone in serum. Horm Res 1999;51:27-9. (Pubitemid 29301280)
11. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 1991;12:424-49.
12. Jan T, Shaw MA, Baumann G. Effects of growth hormone-binding proteins on serum growth hormone measurements. J Clin Endocrinol Metab 1991;72:387-91. (Pubitemid 21921704)
13. Ebdrup L, Fisker S, Sorensen HH, Ranke MB, Orskov H. Variety in growth hormone determinations due to use of different immunoassays and to the interference of growth hormone-binding protein. Horm Res 1999;51:20-6. (Pubitemid 29301279)
14. Hansen TK, Fisker S, Hansen B, Sorensen HH, Christiansen JS, Jorgensen JO, Orskov H. Impact of GHBP interference on estimates of GH and GH pharmacokinetics. Clin Endocrinol 2002;57:779-86. (Pubitemid 36963006)
15. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormonereceptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7. (Pubitemid 30211048)
16. Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ. Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol 2007;156:315-9. (Pubitemid 46554499)
17. Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 2012;97:1187-93.
18. Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 2007;92:3374-7. (Pubitemid 47435307)
19. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab 2001;86:3304-10. (Pubitemid 32673502)
20. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, et al. Growth hormone (GH) receptor blockade with a peg-modified GH (B2036-peg) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 1999;84:2098-103. (Pubitemid 30647040)
21. Strasburger CJ, Kostyo J, Vogel T, Barnard GJ, Kohen F. The antigenic epitopes of human growth hormone as mapped by monoclonal antibodies. Endocrinology 1989;124:1548-57. (Pubitemid 19082732)
22. NCCLS. Evaluation of precision performance of quantitative measurement methods; approved guideline - second edition 2004. NCCLS document EP5-A2 (ISBN 1-56238-542-9). Wayne (PA): CLSI; 2004.
23. NCCLS. Protocols for determination of limits of detection and limits of quantitation; approved guideline 2004. NCCLS document EP17-A (ISBN 1-56238-551-8). Wayne (PA): CLSI; 2004.
24. Wu Z, Bidlingmaier M, Friess SC, Kirk SE, Buchinger P, Schiessl B, Strasburger CJ. A new non-isotopic, highly sensitive assay for the measurement of human placental growth hormone: development and clinical implications. J Clin Endocrinol Metab 2003;88:804-11. (Pubitemid 36207826)
25. Carlsson LM, Rowland AM, Clark RG, Gesundheit N, Wong WL. Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood. J Clin Endocrinol Metab 1991;73:1216-23. (Pubitemid 121000695)
26. Doehner W, Pflaum CD, Rauchhaus M, Godsland IF, Egerer K, Cicoira M, et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol 2001;145:727-35. (Pubitemid 33133679)
27. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-60. (Pubitemid 29425900)
28. Wood P. Growth hormone: its measurement and the need for assay harmonization. Ann Clin Biochem 2001;38:471-82. (Pubitemid 32846052)
29. Hayakawa M, Shimazaki Y, Tsushima T, Kato Y, Takano K, Chihara K, et al. Metabolic effects of 20-kilodalton human growth hormone (20k-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20k-hGH. J Clin Endocrinol Metab 2004;89:1562-71. (Pubitemid 38507903)
30. Muller AF, Janssen JA, Hofland LJ, Lamberts SW, Bidlingmaier M, Strasburger CJ, van der Lely AJ. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J Clin Endocrinol Metab 2001;86:590-3. (Pubitemid 32207463)
31. Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J Clin Endocrinol Metab 2002;87:5737-45. (Pubitemid 36034384)
32. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 2003;13:171-84. (Pubitemid 36980706)
33. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808-16. (Pubitemid 28513555)
34. Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002;87:3142-7. (Pubitemid 34816356)
35. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 2008;93:1254-62. (Pubitemid 351519718)
36. Rakover Y, Lavi I, Masalah R, Issam T, Weiner E, Ben-Shlomo I. Comparison between four immunoassays for growth hormone (GH) measurement as guides to clinical decisions following GH provocative tests. J Pediatr Endocrinol Metab 2000;13:637-43. (Pubitemid 30435935)
37. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 1994;78:1312-9. (Pubitemid 24180997)
38. Markkanen H, Pekkarinen T, Valimaki MJ, Alfthan H, Kauppinen-Makelin R, Sane T, Stenman UH. Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls. Clin Chem 2006;52:468-73.
39. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9. (Pubitemid 32273628)
40. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004;89:495-500. (Pubitemid 38269847)
41. Roemmler J, Steffin B, Gutt B, Sievers C, Bidlingmaier M, Schopohl J. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment. Growth Horm IGF Res 2009;19:245-51.
42. Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brubach K, et al. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 2009;161:27-35.